Cytek Biosciences (CTKB) has announced preliminary unaudited revenue results for 2024, expecting full-year revenue between $200-201 million, representing 4% growth over 2023's $193.0 million. The company faced a $1.0 million negative foreign exchange impact. Fourth quarter revenue is expected to be $57-58 million, showing 11-13% growth compared to Q3 2024, but a 2% decline to flat performance versus Q4 2023. The quarter was impacted by a $1.5 million negative effect from US dollar appreciation and order delays in some markets, although Asia Pacific and Rest of World markets showed strong growth. The company will report detailed financial results and provide 2025 guidance during its earnings call expected in late February 2025.